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ABSTRACT 
Hyperphosphatemia is the key abnormality that sets off a cascade of metabolic events in 
chronic kidney disease (CKD). End stage renal disease (ESRD) patients that undergo 
Continuous Ambulatory Peritoneal Dialysis (CAPD) uses the peritoneal membrane for 
solutes filtration and clearance. The differences on the evaluation of peritoneal 
membrane transport status can affect the rate of toxin removal – serum phosphorus, 
from the systems. The present study aimed to determine the prevalence of CAPD 
patients presented with high phosphate level after starting the treatment, to identify the 
risk factors associated with hyperphosphatemia and to find the significant correlation 
between the phosphate level and the PET characteristics. A retrospective study was 
applied for this research where the medical records of patients were reviewed and 
analyzed between January 2011 to December 2016. Data were collected successfully 
from 74 adult CAPD patients (41 male, 55.4% and 33 females, 44.6%), with mean age of 
51.34 ± 13.75 year-old. In this study, Malays (n= 65, 87.8%) are the largest subjects 
recruited, while Chinese (n= 6, 8.1%) and Indians (n= 3, 4.1%) made the rest of the 
subjects. PET characteristics of CAPD patients showed 11 patients had high 
characteristic (14.9%), 24 high average (32.4%), 26 low average (35.1%) and 5 low (6.8%).  
There were 37 CAPD patients (50%) presented with high phosphate level after starting 
the treatment. Simple linear regression revealed that age (p = 0.0052), serum calcium (p 
= 0.0090), serum albumin (p = 0.0244), normalized protein catabolic rate (nPCR) (p = 
0.0126), intact parathyroid hormone (iPTH) (p = 0.0012), total creatinine clearance (p = 
0.0470), residual renal creatinine clearance (p = 0.390) and 24-hours urine volume output 
(p = 0.0060) were risk factors associated with hyperphosphatemia. Pearson’s correlation 
analysis showed there was no significant correlation between phosphate level and PET 
characteristics (r = -.232, p = 0.070) while there was significant correlation between PET 
characteristics and peritoneal solute clearance (r = 0.4748, p < 0.001). In conclusion, 
serum phosphate level may be associated with daily dietary intake, metabolism and 
dialysis adequacy. There was no correlation between serum phosphate level and PET 
characteristic suggesting the rate of the toxin removal might not been affected by the 
differences on peritoneal membrane characteristics suggesting a further understanding 
on transport status in terms of its mechanism of toxin removal. 
 
KEYWORDS: CAPD, serum phosphate level, hyperphosphatemia, PET characteristics, 
solute clearance. 
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INTRODUCTION 
The first introduction of continuous ambulatory peritoneal dialysis (CAPD) was published in 
Annals of Internal Medicine by Robert Popovich and his colleagues in 1978 that explained their 
understanding with the new technique and it has been proven to be an alternatives for 
hemodialysis as well as intermittent peritoneal dialysis for treating uremic syndrome 
(Oreopoulos & Thodis, 2010). CAPD follows the rule of osmotic pressure (osmotic gradient) and 
ultrafiltration where solutes and water will move across the semipermeable membrane that can 
be described as movement from blood to dialysate or/and from dialysate to blood according to 
concentration gradients.  
The physiology of peritoneal membrane influence mass transport during peritoneal 
dialysis, thereby affecting its therapeutic efficacy. The membrane is lined by mesothelium cells 
that produced thin layer of peritoneal fluid. Under the mesothelium layer there is a gel-like 
interstitial containing the connective tissue, capillaries and lymphatic (Lokesh & Arunkumar, 
2013). The effective peritoneal surface area is critical for dialysis and it depends on the 
vascularity of the peritoneum as well as its surface area (Daugirdas, Blake, & Ing, 2007). It is to 
be note that the peritoneal cavity is different between every patient and within a patient under 
different conditions. The rate and extend of the solute transport basically, determined by the 
proximity of capillaries to the peritoneal surface and the difference in characteristic of 
peritoneal transport among different patients.  
Thus, a systematic equilibration test is developed to evaluate the peritoneal membrane 
transport rates called Peritoneal Equilibration Transport (PET) which is first introduced by 
Zbylut J.Twardowski in 1987. The PET results allow the patients to be classified into high 
transporter (H), low transporter (L), high average transporter (HA) and low average transporter 
(LA) according to the solutes clearance rate (Twardowski et al., 1987). The status of peritoneal 
transporter influenced the rate of solute clearance in a way that it is parallel with the membrane 
effectiveness for ultrafiltration. The adequacy of ultrafiltration for waste product is crucial in 
chronic kidney disease (CKD) patients.  
Phosphate is one of many waste products where the accumulation level becoming 
concern to the nephrologist and health professionals. Phosphate overload have become known 
and has been successfully analyzed to have association to the progression of CKD, left 
ventricular hypertrophy and vascular calcification particularly coronary artery calcification that 
eventually contribute to increase rate of mortality. Concern regarding development of CKD-
MBD begin to appear even in early stages of CKD as in long term it eventually contribute to the 
pathogenesis of renal osteodystrophy particularly femur fracture. In CKD, hyperphosphatemia 
depict a signal that mineralization occur in order to compensate for the failure phosphate 
storage function in the skeleton.  
Accumulated phosphate can only be removed though dialysis but differences in the 
thickness of peritoneal cavity may be the limitation. However, much uncertainty still exists 
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about the relation between PET status and the solutes removal. Due to this concern, study is 
done to correlate the differences in the transporter status (H, HA, L, LA) towards the 
effectiveness of phosphate removal from the body. The prevalence of CAPD patients presented 
with high phosphate level after starting the treatment is determine as well. In addition, the 
predictors that could possibly contribute to the increase of phosphate level among CAPD 
patients in HTAA is determine to assist the nephrologists as debate continues about the best 
strategies for the management of ESRD patients.  
 
METHODS 
Study population 
A retrospective study was applied for this research where the hospital records of patients were 
reviewed and analyzed in order to answer the objectives of this research among end stage renal 
disease (ESRD) patient undergoing CAPD treatment from January 2011 to December 2016. The 
study was conducted at CAPD Unit, Nephrology Department, HTAA. Inclusion criteria: ESRD 
patients older than 18 years of age who were on continuous ambulatory peritoneal dialysis 
(CAPD). Exclusion criteria: non ESRD patients, patients with ESRD but not treated by CAPD, 
passed away patients, and those initially treated with CAPD but then converted to other 
dialysis modalities. 
Sample size calculation was done by referring to the total number of continuous ambulatory 
peritoneal dialysis (CAPD) patients in HTAA from January 2011 till December 2016 as reference 
population. The unpublished data from CAPD audit showed that total number of CAPD 
patients in Nephrology Clinic, HTAA between the timeline was 182 patients. In order to achieve 
95% of confidence level with 5% of confidence interval, the minimum sample size needed for 
this study is 137. After considering all the criteria as above, 74 patients were included in this 
study.  
Data collection 
The following data were collected for all patients: socio-demographic details (identification 
number, age, sex, race, body mass index (BMI), duration of CAPD treatment, primary disease 
and comorbidities) and biochemical analysis data (serum phosphate, serum calcium, intact 
parathyroid hormone (iPTH), serum albumin, normalized protein catabolic rate (nPCR), 
peritoneal equilibration test (PET) characteristic, calcium carbonate (CaCO3), total creatinine 
clearance, residual renal creatinine clearance, 24-hours urine volume output). Socio-
demographics data were recorded at baseline while for biochemical analysis data were collected 
from the latest results. 
 
Statistical test 
Descriptive test was used for all demographic data listed. Continuous data were expressed as a 
proportion and medians or means ± standards deviation, according to the nature of the data for 
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this study while categorical variables were expressed as percentages. Simple linear regression 
was used to identify the possibly independent predictors of hyperphosphatemia among 
continuous ambulatory peritoneal dialysis (CAPD) patients. The search of association between 
phosphate level and the PET characteristic in CAPD patients were test using Pearson’s 
correlation coefficients. Statistical evaluation was carried out with the Statistical Package for the 
Social Sciences (SPSS) version 22.0 and Graph Pad Prism 6, at a level of p-value less than 0.05 (p 
< 0.05) is considered statistically significant. 
 
RESULTS 
Between January 1, 2011, and December 31, 2016, a total of 74 adult patients on CAPD 
modalities were enrolled for this study. The average duration of peritoneal dialysis is 21.9 ± 16.1 
months (range 3-73 months). Age was defined with age at the time of data collection and was 
classified into 6 groups; 15-24, 25-34, 35-44, 45-54, 55-64, ≥ 65. The patient’s mean age is 51.34 ± 
13.75 year (range 24-82) with dominantly 28.38% in the age group 55-64 years and only 2.7% in 
the age group of 15-24 years. The overall trends for patient’s age distribution to be increasing 
but then decline for patient’s age more than 65 years.  There was no further documentation on 
the type of diseases or conditions that contributed to the unknown causes of the patients’ 
medical records as the exact diagnosis is not known. All patients received calcium carbonate 
(CaCO3) treatment appropriately in accordance to the phosphate level following strictly the 
Kidney Disease: Improving Global Outcomes (KDIGO) (2003) guidelines and were not 
influencing this study. The population characteristics and distribution can be observed in Table 
1. 
Table 1 Characteristics of the Peritoneal Dialysis Patients (n = 74) 
 n/% 
Gender n (%)  
      Male 41 (55.4%) 
      Female 33 (44.6%) 
Age (years)  
       Mean ± SD 51.34 ± 13.75 
       Range 24-82 
       15-24 years old 2 (2.7%) 
       25-34 years old 10 (13.52%) 
       35-44 years old 11 (14.86%) 
       45-54 years old 18 (24.32%) 
       55-64 years old 21 (28.38%) 
        ≥65   years old 12 (16.22%) 
Ethnicity n (%)  
       Malay     65 (87.8%) 
       Chinese 6 (8.1%) 
CORRELATION BETWEEN PHOSPHATE LEVEL AND PET… 
 
 
171 
       Indian 3 (4.1%) 
BMI (kg/m2) n (%)  
        Underweight 6 (8.1%) 
        Normal 38 (51.4%) 
        Overweight 21 (28.4%) 
        Obese 9 (12.2%) 
Primary Disease n (%)  
        Diabetes 26 (35.1%) 
        Glomerulonephritis 1 (1.4%) 
        Hepatitis B 1 (1.4%) 
        Sytemic Lupus Erythematosus (SLE) 3 (4.1%) 
        Unknown Disease 42 (56.8%) 
Comorbidities n (%)  
       Hypertension (HTN) 38 (51.4%) 
       Hyperparathyroidism (HPT) 18 (24.3%) 
       Hypertension/Hyperparathyroidism 11 (14.9%) 
       Anemia/ Hyperparathyroidism 7 (9.5%) 
 
Peritoneal Equilibration Test (PET) characteristics 
The distribution of PET characteristics of all CAPD patients (n= 66) in our population was 
predominant low average transport status followed by high average, high and low transport 
status with 35.1% (n= 26), 32.4% (n= 24), 14.9% (n= 11) and 6.8% (n= 5) correspondently. In 
addition, patients with high phosphate level (n= 37, 50%) also characterized according to 
peritoneal transport status and shows that 40.5% (n= 15) classified under low average, followed 
by high average, high and low transport status with 29.7% (n= 11), 10.8% (n= 4) and 8.1% (n= 3) 
respectively. 
Serum phosphate level 
The present study discovered that there were 37 CAPD patients (50%) presented with high 
phosphate level after starting the treatment while the rest shows normal phosphate level. From 
a total of 55.4% (n= 41) male patients on CAPD modalities, 57% (n= 21) presented with high 
phosphate level. While, 43% (n= 16) female patients presented high phosphate level from a total 
of 44.6% (n= 33). 
Risk factors of hyperphosphatemia 
Linear regression was performed to predict and analyze the association between the serum 
phosphate levels with other factors. The most striking result to emerge from the data is that 
normalized protein catabolic rate (nPCR), serum calcium, serum albumin, intact parathyroid 
hormone (iPTH) and 24-hours urine volume output taken together, these results suggest that 
there were significant association between the factors with the serum phosphate level. Factor 
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like age, total creatinine clearance, residual renal creatinine clearance were found to be inversely 
associated with this level. In contrast, body mass index (BMI) and peritoneal dialysis duration, 
were not significantly associated with the amount of serum phosphate (Table 2). 
 
Table 2 Factors associated with serum phosphate level 
FACTOR MEAN± SD r p-value 
Age (years) 51.34 ± 13.75 -0.321 0.0052* 
BMI (kg/m2) 24.5 ± 5.3 -0.102 0.3876 
Dialysis Duration (month) 21.9 ± 16.1 0.097 0.4131 
nPCR (g/kg*d) 0.72 ± 0.18 0.299 0.0126* 
Serum Calcium 2.22 ± 0.29 0.302 0.0090* 
Serum Albumin (g/dl) 34.96 ± 5.51 0.261 0.0244* 
iPTH (per 100ng/dl) 186.88 ± 148.43 0.373 0.0012* 
Total Creatinine Clearance 60.22 ± 19.87 -0.220 0.0470* 
Residual Renal Creatinine 
Clearance 
15.20 ± 20.62 -0.422 0.0390* 
24-hours urine volume output 294.37 ± 330.97 0.441 0.0060* 
*significant with p-value < 0.05 
 
Association of phosphate level and PET characteristics 
A scatter diagram and a Pearson’s product moment correlation were used to assess the 
relationship between phosphate level and peritoneal membrane characteristics. Prior to direct 
comparison between phosphate level and peritoneal membrane status, however, have not 
shown a clear significant difference in this analysis. Data analysis showed there was a weak, 
negative correlation between phosphate level and PET characteristics (r = -.232, n= 66, p = 
0.070). This study then attempted to examine based on peritoneal membrane transport alone 
and finding shows that it is significantly correlated with peritoneal clearance (r= 0.4748, n= 66, p 
< 0.001). High and high average membrane status have higher peritoneal clearance while low 
and low average membrane status have a lower peritoneal clearance (Table 3). 
 
Table 3 Transport categories and peritoneal clearance 
Membrane transport type MEAN± SD 
Peritoneal clearance (L/week/1.73 m2) 
High Transport 71.87 ± 22.07 
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High Average Transport 59.45 ± 16.63 
Low Average Transport 55.10 ± 20.68 
Low Transport 33.58 ± 6.03 
 
 
DISCUSSIONS 
In this retrospective study, it is demonstrated that 74 adult patients were admitted for 
continuous ambulatory peritoneal dialysis (CAPD) treatment in Hospital Tengku Ampuan 
Afzan (HTAA). Gender differences have been identified where end stage renal disease (ESRD) 
cases for male are notably higher than females. It is important to evaluating clinical data by 
gender because of men’s and women's physiology differences. These results are consistent with 
those of other studies and suggested that predictors leading to decline in renal function are 
related with gender differences (Halbesma et al., 2008; Hecking et al., 2014).  
Comparing the distribution of ethnicity of CAPD patients treated in HTAA showed that 
Malay race covers the majority of the study population compare to Chinese and Indian. A 
possible explanation for this might be that the patients was from the states of Pahang in 
Malaysia, where probably the dominant ethnic group is Malay. Study by Sabanayagam and 
colleagues in 2013 stated, the differences of ethnicity distribution in CKD might be influenced 
by the association with prevalence disease such as hypertension and medication received by the 
patients. Higher cases of CKD in the elderly population has been connected to the fact that renal 
function declines with age. One unanticipated finding in this study is that predominance body 
mass index (BMI) categories of CAPD patients was normal followed by overweight, obese and 
underweight. Surprisingly, other findings indicate so called the obesity paradox where being 
overweight/obese or high value of BMI are actually a protection and associated with improve 
survival on hemodialysis (Ikizler, Stenvinkel, & Lindholm, 2008) but mixed result is seen for 
peritoneal dialysis patients (Park et al., 2014). The association of BMI and peritoneal dialysis 
survival has been inconsistent as of result on previous study shows neutral (Aslam, Bernardini, 
Fried, & Piraino, 2002) beneficial (Johnson et al., 2000) and damaging (McDonald, Collins, & 
Johnson, 2003) effect of high BMI toward peritoneal dialysis outcome. 
The status in peritoneal membrane transport is related to the long term survival dialysis 
patients. High transport status demonstrated to be associated with the mortality rate and an 
independent predictor for technique failure for patients that subscribed to CAPD modalities 
(Rumpsfeld, Mcdonald, & Johnson, 2006). However, the findings by Huang and colleagues 
(2014) do not support previously findings where high transport status does not necessarily add 
to adverse effect in survival rate when diabetes status included, suggesting that, factor such as 
causes of end stage renal disease (ESRD) may influenced patients transport status. To add to 
that, other findings by Park and colleagues (2001), Paniagua and colleagues (2002), and Perl and 
colleagues (2009) also reported that high peritoneal transport status failed to independently 
influence mortality rate in CAPD patients. This inconsistency not clearly represented but may 
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be due to differences in the primary diseases and comorbidities of ESRD, racial or ethnicity of 
patients, method of the PET test and a combination of new and prevalent cases. These findings 
may help to understand and be used to guide dialysis modalities that are appropriate for each 
patients when the evaluation of peritoneal membrane be performed routinely. In further 
management, the use of this data could be a means optimizing medical prescription according 
to the result of the peritoneal membrane status. 
An initial objective of the research was to determine the prevalence of CAPD presented 
with hyperphosphatemia in Nephrology Clinic, HTAA after starting the treatment. In this 
population it is found that half of the patients (50%, n= 37) with 21 male (56.8%) and 16 female 
(43.2%) were presented with a high phosphate level. This result may suggest that 
hyperphosphatemia should be taken into concern and prior studies have highlighted the 
importance of maintaining phosphate level in end stage renal disease (ESRD) patients. This 
finding has important implications for the management of hyperphosphatemia in dialysis 
patients that include dietary management and the use of medication and phosphate binders 
according to the stages of CKD development. Further studies, which take these variables into 
account, will need to be undertaken.  
As mention previously, understanding the importance of serum phosphate level is 
crucial for end stage renal disease (ESRD) patient as it is contribute to the risk of diseases where 
the controlling may be useful to improve ESRD prognosis. Therefore, an additional findings on 
hyperphosphatemia risk factors was performed to achieve better phosphate control.  
In this study we found that normalized protein catabolic rate (nPCR), serum calcium, 
serum albumin, intact parathyroid hormone (iPTH), 24-hours urine volume output, age, total 
creatinine clearance, residual renal creatinine clearance  were independent risk factors for 
hyerphosphatemia. Increased or decreased amount of serum phosphate level is influenced by 
various variables that comprise of phosphate intake, phosphate absorption and phosphate 
removal. It can therefore from these results be assumed that, dietary phosphate intake, dialysis 
adequacy and calcium phosphate metabolism determines the serum phosphate level. Hence, it 
is useful to be noted that directly treating phosphate through restriction and control of dietary 
phosphate intake may be useful in slowing and controlling the progression vascular 
calcification, cardiovascular and bone disease (CKD-MBD) as well as secondary 
hyperparathyroidism (SHPT) in later kidney disease stages. In order to provide a better clinical 
outcomes, earlier approach of phosphate binder therapy, prescription of supplement (vitamin 
D) concomitant to dietary intake was suggested (Martin & González, 2011).  
This study set forth with the aim of assessing the relationship of the PET characteristics 
toward phosphate level among CAPD patients in Nephrology Clinic, HTAA. This study did not 
conclude a significant correlation between serum phosphate level and peritoneal membrane 
transport status when direct correlation was performed. In this study, peritoneal membrane 
characteristic was determined according to the calculation of peritoneal membrane creatinine 
transport status. According to the principle of diffusion across the peritoneal membrane, 
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phosphorus is considered as large size molecules based on its molecular weight, hence, rate of 
phosphate clearance across the peritoneal membrane is more likely to be similar to creatinine 
(Nissenson & Fine, 2017).  
Previous research however, mentioned that peritoneal creatinine transporter (D/P Cr) 
and clearance (CrCl) cannot be used as substitutes to indicate peritoneal phosphate transport 
status (D/P Ph) and phosphate clearance (PhCl) from which in the result reported that D/P Cr 
and CrCl does not show any significant differences between normal and hyperphosphatemia 
patients while those with hyperphosphatemia showed significant association with D/P Ph (p = 
0.019) and PhCl (p = 0.06) (Courivaud & Davenport, 2015). Contradictory to this, multivariate 
regression analysis in a retrospective study stated that creatinine clearance can be a substitutes 
to phosphate clearance as there is strong independent association between both (Badve, 
Zimmerman, Knoll, Burns, & McCormick, 2008). Another study by López-guerra, Rodríguez-
garcía, and Rodríguez-castellanos in 2014 also mentioned that phosphate clearance showed to 
be significantly correlated with creatinine clearance in total, dialysate and urine measurement 
with p < 0.05. The inconsistency of current finding with preceding study suggest the possibility 
on the different in the 4-hours (D/P ratio) solute range of PET classification and the methods of 
the PET test. 
The main limitation of our study were a short study period and relatively small patient 
population size. To counteract those limitations, a prospective or retrospective cohort study can 
be done. Continuity of research in regard of these indicators are recommended on the basis of 
lacking on the knowledge about phosphorus transport especially for patients undergo 
peritoneal dialysis modalities in clinical practices suggesting that it may possible to compare the 
variables between CAPD modalities with other type of treatment such as APD. Large sample 
size that possibly include other government and/or private hospitals and/or clinics could be 
included for this study. Multicenter study that covers other hospitals such as from other district 
in Pahang or possibly expand it to Malaysia that covers major hospital in the Peninsular so that 
can include all main corridors; northern, westerns, eastern and southern.  
 
CONCLUSION 
In conclusion, the prevalence of hyperphosphatemia among continuous ambulatory peritoneal 
dialysis (CAPD) patients is considered as high and have become one of the major concern by 
nephrologist and health professionals due to the clinical consequences. Based on this research, 
level of serum phosphate was significantly, positively associated with nutritional markers 
(normalized protein catabolic rate (nPCR) and serum albumin), intact parathyroid hormone 
(iPTH), serum calcium and 24- hours urine volume output. Serum phosphate level was 
significantly, inversely associated with age and dialysis adequacy (total creatinine clearance and 
residual renal creatinine clearance). While, body mass index (BMI) and duration on dialysis 
were found to be not significantly associated with serum phosphate level among CAPD patients 
in HTAA. In this investigation, the main goal was to assess the correlation between serum 
phosphate level and peritoneal equilibration test characteristics or the transport status. 
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Returning to the question posed at the beginning of this study, it is now possible to state that 
there was no significant correlation between serum phosphate level and PET characteristics 
given the rate of the toxin removal (phosphate) should not been affected by the differences on 
peritoneal membrane status. The study has gone some way towards enhancing our knowledge 
on the important of adequacy and efficiency of solute clearance in dialysis patient to reduce rate 
of morbidity and mortality and subsequently improve patient’s management.  
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